Fenofibrate
Fenofibrate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Fenofibrate; Generic name: FENOFIBRATE; Drug class: Peroxisome Proliferator Receptor alpha Agonist [EPC].
| Brand name | Fenofibrate |
|---|---|
| Generic name | FENOFIBRATE |
| Drug class | Peroxisome Proliferator Receptor alpha Agonist [EPC] |
| Manufacturer | Sun Pharmaceutical Industries, Inc. |
| Used for | 1 INDICATIONS AND USAGE Fenofibrate tablets are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1). For treatment of adult patients with severe hypertriglyceridemia (1.2). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LD |
| Dosage | 2 DOSAGE AND ADMINISTRATION Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily (2.2). Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg (2.3). Renally impaired patients: Initial dose of 48 mg once daily (2.4). Geriatric patients: Select the dose on the basis of renal function (2.5). Maybe taken without regard to meals (2.1). 2.1 General Considerations Patients should be placed on an appropriate lipid-lowering diet befo |
| Active ingredient(s) | FENOFIBRATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=125bbd7e-86a2-4209-90a5-ad353e572d1b |